Patients with new-onset type 1 diabetes did not experience accelerated declines of beta cell function if they received intradermal injections of human leukocyte antigen-DR4-restricted immunodominant proinsulin peptide, according to a study in Science Translational Medicine. The placebo group used 50% more daily insulin after a year, while insulin use remained steady in the treatment group.
Research examines safety of proinsulin peptide immunotherapy in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.